[High-dose thalidomide for severe idiopathic obscure gastrointestinal bleeding in a patient at high-thrombotic risk]

Gastroenterol Hepatol. 2013 Jan;36(1):35-8. doi: 10.1016/j.gastrohep.2012.03.015. Epub 2012 Jun 29.
[Article in Spanish]

Abstract

We report the challenging case of an 81-year-old woman on dual antiplatelet therapy with recurrent strokes, who presented with severe obscure gastrointestinal bleeding. A thorough diagnostic work-up, including capsule endoscopy, double balloon enteroscopy, arteriography, exploratory laparotomy and mouth-to-anus intraoperative enteroscopy, failed to reveal the source of the bleeding. During a 2-year period, the patient required 117 packed red blood cell units, despite withdrawal of antiplatelet drugs and empirical therapy with high-dose somatostatin analogues. The patient was administered an increasing dosage of thalidomide, up to 300 mg/day, with thromboembolism prophylaxis for 3 months, with no clinical response. The bleeding stopped for 3 months after heparin was discontinued, but thalidomide had to be withdrawn owing to adverse effects. Since bleeding recurred a month later, the patient underwent another 3-month course of thalidomide. The patient has not required further blood transfusion after a 1-year follow-up.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged, 80 and over
  • Angiogenesis Inhibitors / administration & dosage*
  • Female
  • Gastrointestinal Hemorrhage / drug therapy*
  • Humans
  • Risk Assessment
  • Severity of Illness Index
  • Thalidomide / administration & dosage*
  • Thrombosis

Substances

  • Angiogenesis Inhibitors
  • Thalidomide